Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 155,000 shares, a growth of 105.0% from the January 15th total of 75,600 shares. Based on an average daily volume of 185,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 29.1% of the company’s shares are sold short.

Bone Biologics Stock Performance

Bone Biologics stock traded down $0.02 during midday trading on Thursday, reaching $1.05. 12,360 shares of the stock traded hands, compared to its average volume of 222,576. The company has a 50-day simple moving average of $1.06 and a two-hundred day simple moving average of $1.40. Bone Biologics has a 12-month low of $0.80 and a 12-month high of $4.49.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.